* Axitinib (Inlyta), a tyrosine kinase inhibitor, has recently been approved for the treatment of advanced kidney cancer when other therapy hasn't been successful. Taken orally twice a day, axitinib prevents angiogenesis, tumor growth, and cancer progression.
* Common adverse effects include diarrhea, hypertension, fatigue, anorexia, nausea, loss of voice, hand–foot syndrome, weight loss, vomiting, weakness, and constipation.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org.